Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

98
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
98
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

102
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
102
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

112
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
112
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

588
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
588
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

77.1K
Overview
77.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same author

Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy.

Bone marrow transplantation·2026
Same author

Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes.

Transplantation and cellular therapy·2026
Same author

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Blood advances·2026
Same author

Rapid HHV-6 Clearance Following Preemptive Short-Course Foscarnet in Allogeneic Stem Cell Transplant Recipients.

American journal of hematology·2026
Same author

Cultural Adaptation and Feasibility of an Inpatient Yoga Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation in Tanzania, India, and the United States: A Study Protocol.

Global advances in integrative medicine and health·2026

Related Experiment Video

Updated: Oct 26, 2025

Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells
10:44

Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells

Published on: February 2, 2011

48.9K

Decrease post-transplant relapse using donor-derived expanded NK-cells.

Stefan O Ciurea1, Piyanuch Kongtim2, Doris Soebbing3

  • 1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. sciurea@uci.edu.

Leukemia
|July 27, 2021
PubMed
Summary
This summary is machine-generated.

High-dose donor-derived natural killer (NK) cells significantly reduced relapse rates in patients undergoing haploidentical stem-cell transplantation for myeloid malignancies. This NK cell therapy improved disease-free survival and was well-tolerated, showing promise for reducing relapse post-transplant.

More Related Videos

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
08:42

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

Published on: January 15, 2018

11.3K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.6K

Related Experiment Videos

Last Updated: Oct 26, 2025

Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells
10:44

Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells

Published on: February 2, 2011

48.9K
Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
08:42

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

Published on: January 15, 2018

11.3K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.6K

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Relapse remains a significant challenge after haploidentical stem-cell transplantation (HSCT) for myeloid malignancies.
  • Natural Killer (NK) cells play a crucial role in anti-leukemic responses post-HSCT.
  • Ex vivo expanded donor-derived NK cells offer a potential strategy to enhance anti-leukemic immunity.

Purpose of the Study:

  • To evaluate the safety and efficacy of high-dose mb-IL21 expanded donor-derived NK cells in reducing relapse after haploidentical HSCT.
  • To assess the impact of NK cell therapy on immune reconstitution and disease-free survival (DFS).
  • To compare outcomes with a contemporaneously treated control cohort.

Main Methods:

  • Phase I/II clinical trial involving 25 patients with myeloid malignancies receiving haploidentical HSCT.
  • Administration of three doses of ex vivo expanded donor NK cells (1x10^5-1x10^8 cells/kg/dose) on specific days post-transplant.
  • Comparison with a case-matched cohort of 160 patients from the CIBMTR database.

Main Results:

  • Significantly lower 2-year relapse rate in the NK cell group (4%) compared to controls (38%, p=0.014).
  • Improved 2-year DFS in the NK cell group (66%) versus controls (44%, p=0.1), particularly in patients without donor-specific antibodies (DSA).
  • NK cell therapy was safe, promoted NK cell-dominant immune reconstitution, preserved T-cell recovery, and led to a dose-dependent increase in circulating NK cells.

Conclusions:

  • Administration of donor-derived expanded NK cells post-haploidentical HSCT is safe and effective in reducing relapse.
  • NK cell therapy enhances early immune reconstitution and improves DFS in patients with myeloid malignancies.
  • This approach represents a promising strategy for improving outcomes in haploidentical HSCT.